AstraZeneca Pharma India signs LoI with Reliance’s Strand Life Sciences for healthcare tie-up


AstraZeneca Pharma India Ltd has signed a letter of intent (LoI) with Strand Life Sciences Private Ltd, a genomics research and diagnostics company and a subsidiary of Reliance Industries, to explore opportunities for collaboration in healthcare in India.

In a regulatory filing on Tuesday, November 17, the pharmaceutical company said the agreement would allow both sides to explore potential areas of collaboration in the Indian healthcare sector. The announcement, however, does not specify the nature or scope of the proposed partnership.

AstraZeneca Pharma India clarified that Strand Life Sciences is not a related party and that the execution of the LoI does not constitute a related-party transaction.

Following the announcement, shares of AstraZeneca Pharma India were trading 2.4% higher at ₹6,175.5 on the BSE, up ₹142.75, as of 2:43 pm.

The development comes days after the pharmaceutical company reported a 14.9% year-on-year increase in net profit to ₹62.3 crore for the second quarter of FY27, compared with ₹54.2 crore in the corresponding period last year.

Revenue from operations rose 30.4% to ₹729 crore from ₹559 crore in the year-ago quarter. Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 26.7% to ₹95 crore from ₹75 crore. However, the EBITDA margin moderated to 13.1% from 13.4% a year earlier.

Also Read: AstraZeneca Pharma Q2 Results: Net profit up 15% on growth across key therapy areas

The company attributed its revenue growth to consistent performance across its oncology, biopharmaceuticals and rare disease therapy areas.

For the first half of FY27, revenue from operations stood at ₹1,411.9 crore, registering growth of around 30% over the corresponding period of the previous financial year.

Commenting on the performance, Praveen Rao Akkinepally, Country President and Managing Director of AstraZeneca Pharma India, said the continued growth reflected the strength of the company’s science-led portfolio and its ability to translate innovation into meaningful outcomes for patients in India.

We are accelerating our efforts across oncology, biopharmaceuticals and rare disease. Our focus remains on building strong partnerships across the healthcare ecosystem to bring innovative medicines to more patients faster and improve health outcomes across the countryHE SAID

NOTE TO READERS

Disclaimer: Reliance Industries Ltd, which owns Jio, is the sole beneficiary of Independent Media Trust that controls Network18, the parent company of CNBCTV18.com.

Home/Market News/

AstraZeneca Pharma India signs LoI with Reliance’s Strand Life Sciences for healthcare tie-up



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *